A Phase 2 interventional study of WIN378 and Placebo in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Windward Bio. Recruiting at 32 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Windward Bio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina — 14 open to participants now, 17 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Argentina.
Among the 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina, this one is the 113th largest by planned enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 5 of the 16 other live ones, and was the 129th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Argentina, United States
Ages 40–80
Eli Lilly and Company · Sites in Argentina, United States, Austria and 15 more countries
Ages 40–75
Pfizer · Sites in Argentina, United States, Australia and 15 more countries
Ages 35–80
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 30 · Phase 3 74 · Phase 4 13
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 872 across the 123 interventional studies, 950 across the 8 observational. Of the 109 that completed or were terminated, 75 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 131 have an industry lead sponsor. The 10 most frequent:
Windward Bio is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Windward Bio has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
4 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07082738AstraZenecaA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | 2027-08-31 |
| NCT06981078Upstream Bio Inc.A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD). Participants will continue their standard background COPD therapy. Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
WIN378 SC injections will be administered
Drug: WIN378
WIN378 SC injections will be administered
Drug: WIN378
Placebo SC injections will be administered
Drug: Placebo
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
Placebo matching WIN378
Number of participants with Adverse Events (AEs)
Time frame: Week 0 - Week 36
Number of participants with Serious Adverse Events (SAEs)
Time frame: Week 0 - Week 36
Change from baseline in systolic blood pressure (mmHg)
Time frame: Week 0 - Week 36
Change from baseline in diastolic blood pressure (mmHg)
Time frame: Week 0 - Week 36
Change from baseline in pulse rate (beats/minute)
Time frame: Week 0 - Week 36
Change from baseline in respiratory rate (breaths/minute)
Time frame: Week 0 - Week 36
Change from baseline in oxygen saturation (%)
Time frame: Week 0 - Week 36
Change from baseline in body weight (kg)
Time frame: Week 0 - Week 36
Change from baseline in body mass index (kg/m^2)
Time frame: Week 0 - Week 36
Change from baseline in body temperature (°C)
Time frame: Week 0- Week 36
Change from baseline in clinical chemistry laboratory assessments
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
Time frame: Week 0 - Week 36
Change from baseline in haematology laboratory parameters
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
Time frame: Week 0 - Week 36
Change from baseline in coagulation laboratory parameters
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
Time frame: Week 0 - Week 36
Change from baseline in urinalysis parameters
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
Time frame: Week 0 - Week 36
Change from baseline in electrocardiogram QT interval
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
Time frame: Week 0 - Week 36
WIN378 Serum concentration (PK)
Time frame: Week 0 to week 36
Change from baseline in Blood Eosinophil Count
Time frame: Week 0 to Week 24
Change in Fractional Exhaled Nitric Oxide (FeNO)
Time frame: Week 0 to Week 24
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Week 0 to Week 24
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
Time frame: Week 0 to Week 24
Incidence and magnitude of anti-drug antibodies to WIN 378
Time frame: Week 0 to Week 36
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 18 months is above that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Windward Bio